艾灸联合化疗通过Treg/IL-10/TGF-β1轴调控免疫抑制微环境抑制胃癌生长
本研究结合生物信息学与小鼠实验,探讨艾灸联合5-FU对胃癌的作用。结果显示联合治疗抑瘤率45.9%,可降低外周Treg、血清IL-10和TGF-β1并增加CD8+ T细胞浸润,双向重塑免疫微环境。
要点
- 艾灸联合化疗抑瘤率45.9%,优于单用化疗。
- 联合治疗降低外周Treg至3.91%、血清IL-10至51.42 pg/mL、TGF-β1至266.82 pg/mL。
- 联合治疗增加CD8+ T细胞浸润至22.8%,增强抗肿瘤免疫。
核心结论
- 艾灸联合化疗通过双向重塑免疫微环境抑制胃癌生长,同时减轻免疫抑制并增强免疫攻击。
研究设计与样本
- 研究整合生物信息学分析与动物实验,利用TCGA/GTEx数据库分析IL-10和TGF-β1的泛癌表达与预后价值,并建立MFC胃癌小鼠模型评估艾灸(ST36、CV12、CV6、CV4)、化疗(5-FU)及联合治疗的效果。
主要发现
- 生物信息学显示IL-10和TGF-β1在胃癌中上调,与FOXP3+ Treg浸润正相关且预后不良。
- 联合治疗抑瘤率45.9%,降低外周Treg(7.02% vs. 3.91%)、血清IL-10(127.21 vs. 51.42 pg/mL)和TGF-β1(547.84 vs. 266.82 pg/mL),下调肿瘤Foxp3/TGF-β1蛋白。
- 联合治疗显著增加细胞毒性CD8+ T细胞浸润(22.8%),维持强CD8+ T细胞反应。
临床怎么用
- 艾灸联合化疗可能作为胃癌辅助治疗策略,通过调控Treg/IL-10/TGF-β1轴改善免疫微环境。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The immunosuppressive microenvironment poses a major challenge in gastric cancer (GC) therapy. Moxibustion, based on the "Guben Peiyuan" theory, shows potential in oncology, but its immunomodulatory mechanisms in GC remain elusive. METHODS: This study integrated bioinformatics analysis with animal experiments. We analyzed pan-cancer expression and prognostic value of IL-10 and TGF-β1 via TCGA/GTEx databases. A mouse model of MFC gastric cancer was established to evaluate the effects of moxibustion (ST36, CV12, CV6, CV4), chemotherapy (5-FU), and their combination on tumor growth and the immune microenvironment. RESULTS: Bioinformatics indicated that IL-10 and TGF-β1 were upregulated in GC, positively correlated with FOXP3+ Treg infiltration and poor prognosis. In vivo, the moxibustion + chemotherapy combination demonstrated the most potent tumor inhibition (inhibition rate: 45.9%). Mechanistically, the combination therapy exerted a "dual immunomodulatory effect" on the tumor immune microenvironment. It simultaneously suppressed immunosuppressive components, evidenced by reduced peripheral Tregs (7.02% vs. 3.91%), serum IL-10 (127.21 vs. 51.42 pg/mL) and TGF-β1 (547.84 vs. 266.82 pg/mL) levels, and downregulated Foxp3/TGF-β1 protein in tumors. Concurrently, it enhanced anti-tumor immunity, as evidenced by a significant increase in cytotoxic CD8+ T cell infiltration compared to the model group. Notably, the combined therapy elicited the most potent bidirectional immunomodulatory effect: it most effectively suppressed immunosuppressive components (reducing Tregs to 3.91% and serum TGF-β1 to 266.82 pg/mL) while simultaneously maintaining a robust CD8+ T cell response (22.8%), thereby achieving optimal overall remodeling of the tumor immune landscape. CONCLUSION: This study is the first to demonstrate that moxibustion synergizes with chemotherapy to inhibit gastric cancer growth through bidirectional remodeling of the immune microenvironment, simultaneously attenuating immunosuppression and boosting immune attack. Our findings provide a novel mechanistic insight into the integrated "Guben Peiyuan" and Western medicine strategy for GC.
引用
- Wu Y, Ma L, Mao M, et al. Moxibustion combined with chemotherapy inhibits gastric cancer growth by modulating the immunosuppressive microenvironment involving the Treg/IL-10/TGF-β1 axis. Front Pharmacol. 2025. PMID: 41438510. doi:10.3389/fphar.2025.1688182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。